September 30 & October 1, 2014 — Kansas City, Missouri

Introduction

The Drug Enforcement Administration (DEA), Office of Diversion Control, sponsored the 22nd DEA National Conference on Pharmaceutical and Chemical Diversion, September 30-October 1, 2014 in Kansas City, Missouri. Attendees included approximately 71 representatives from various state and local government law enforcement and regulatory agencies. The purpose of this national conference is to educate state and local regulatory and law enforcement personnel on current trends and issues involving pharmaceutical controlled substances and DEA regulated (listed) chemicals. State and local representatives also had an opportunity to interact with DEA representatives to discuss issues or concerns on behalf of their state or region. This conference is held on an annual basis and is one of the mechanisms used by the Office of Diversion Control to foster communication and cooperation with its state and local counterparts.

Conference Presentations

Pharmaceutical Drug Abuse & Trafficking Trends – Ruth A. Carter, Chief, Liaison & Policy Section, DEA HQ

Synthetic Drug & Chemical Abuse & Trafficking Trends – Antonio R. Guzman, Staff Coordinator, Synthetic Drugs & Chemicals Section, DEA HQ

Practitioner/Pharmacist Recidivism – Mari Robinson, J.D., Executive Director, Texas Medical Board and Brian Fingerson, R.Ph., Kentucky Professionals Recovery Network

Pain Management Best Practices – What a Real Pain Management Clinic Looks Like – Hans C. Hansen, M.D., Medical Director, The Pain Relief Centers, LLC

Regulatory Investigation – Susan Langston, Diversion Program Manager, DEA Miami Field Division

Policy Updates – Ruth A. Carter, Chief, Liaison & Policy Section, DEA HQ

Pharmacy Investigation Case Overview – Todd Prough, Special Agent, DEA Worcester, MA Post of Duty

Drug Treatment Issues – Laura K. Howard, J.D., SAMHSA Regional Administrator

Legal Aspects of Overdose Prevention – Corey Davis, J.D., Deputy Director, The Network for Public Health Law – Southeastern Region

Health Care Fraud – Les Hollie, Assistant Inspector General, OIG/HHS and Shimon Richmond, Assistant Special Agent in Charge, OIG/HHS

Synthetic Drug Case Overview – Kent Bailey, Group Supervisor and Eric Christenson, Special Agent, DEA Minneapolis District Office

Prescription Monitoring Programs – Danna E. Droz, J.D., R.Ph., PMP Liaison, NABP

Recent Changes to New York's Controlled Substance Act – Judy Barrett, R.Ph., N.Y. State Department of Health, Bureau of Narcotic Enforcement